6550--HbA1c CPT IDIQ VISN 22

This government Statement of Work outlines the requirements for Glycohemoglobin A1C Analyzer instrumentation for VA Network Contracting Office (NCO) 22 facilities. The scope includes acquiring random access analyzers capable of performing defined clinical parameters with high accuracy and precision, meeting CLIA and CLSI standards. Contractors must provide a continuously stocked inventory of FDA-approved reagents, supplies, and disposables, with emergency deliveries within 24 hours. The "Cost per Test" (CPT) pricing model is specified, encompassing equipment use, all consumables, maintenance, and training. Key technical and operational features include National Glycohemoglobin Standardization Program certification, capacity for Attachment A tests, quick turnaround times, safety features, barcode compatibility, single specimen priority testing, and a minimum of 100,000 patient result storage. The instrumentation must use HPLC or capillary electrophoresis, have FDA approval, and offer full walk-away capabilities. Interface requirements dictate contractor responsibility for hardware, software, and fees for connection to VA systems, including adherence to VA information security standards and collaboration for workflow protocols. Method validation, quarterly sales reports, comprehensive training, emergency and preventative maintenance with strict response times, and free hardware/software upgrades are also mandated. Contractors must characterize and manage all waste according to federal and state regulations, providing detailed documentation and training for VHA staff. The implementation and transition period for all services, including installation and training, is 90 days post-award, with a 30-day acceptance period requiring a 90% effectiveness level. Equipment ownership remains with the contractor, who is responsible for removal. Strict protocols for handling sensitive VA information on electronic media and for medical device hard drives are also outlined.

This document, Attachment C, outlines the estimated annual test volumes and associated costs for Hemoglobin A1c testing across various VISN 22 sites, likely for an RFP or grant application. It details projected test volumes over a base year and four option years, with an estimated 3% annual increase, totaling 2,352,059 tests over five years. The file also lists estimated test volumes and a 5% repeat rate for individual sites like Loma Linda, Long Beach, Phoenix, and San Diego, among others. It requests information on reagents, consumables, and instruments required per test, specifying that pricing should be all-inclusive. The document also includes an "Individual site move" cost for Loma Linda and Long Beach, and an example cost for "Reagent X." This comprehensive overview aims to solicit proposals for pathology services, focusing on Hemoglobin A1c testing within the VISN 22 network.

The Department of Veterans Affairs (VA), VISN 22 Network Contracting Office, has issued a Sources Sought Notice/Request for Information (RFI) for HbA1c testing services. This RFI, identified by Solicitation Number 36C26226Q0069, seeks qualified sources for VISN-Wide HbA1c testing on a Cost Per Test (CPT) or Cost Per Reportable Result (CPRR) basis across multiple VA locations. This is for informational and planning purposes only and does not constitute a solicitation. The VA encourages interested parties to submit company information, including business size (NAICS 325413, 1,250 employees), manufacturer/distributor status, country of origin, federal contract details (FSS GSA, NAC, NASA SEWP), general pricing, UEI number, and capabilities in meeting the Statement of Work. Responses are due by November 13, 2025, at 10:00 a.m. PST, via email to Clift.Domen@va.gov. This RFI will help the Government make informed acquisition decisions, and a formal solicitation may follow.